We will not stand behind non-competitive pricing schemes that undermine the incentive to innovate and invest in drug development, says BIO VP of industry research, David Thomas
Last month, the US Department of Health and Human Services proposed and international pricing index model for Medicare Part B drugs and biologics. The IPI proposal will test whether “phasing down the medicare payment amount” for slected Part B drugs – those predominantly administered by infusion or injection – results in reduced expenditures for the medicare programme.
The US Center for Medicare and Medicaid Services, the department is “taking action on presidnet Trump’s goal to lower drug costs for Medicare beneficiaries by exploring a potential model that seeks to ensure the Medicare programme pays comparable prices for Part B grugs relative to other economically-similar countries.”
However, Biopharmaceutical Industry Organisation’s VP of industry research, David Thomas, has spoken out against the scheme, which he claims not only infulenced record lows on the share market last month, but in the long-term, threatnes innovation across the sector.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“When investors caught wind of this surprising welcome for price controls in America, that US drug prices would be based on benchmarks here in Europe, this torpedoed the biotech stock market to its single largest day drop in seven years,” Thomas told delegates at BIO Europe in Copenhagen last week.
The Nasdaq biotech index dropped 14% in october, and small clinical-stage companies dropped 22%, said Thomas, adding that European biotechs were also affected – dropping 13% last month.
In addtion, the scheme threatens innovation within the emerging biotech industry, Thomas told delegates: “We see… and unprecedented amount of biologic technologies coming out of this sector, which are being developed primarily for rare disease and cancer. This is not the time to remove incentives from the ecosystem that will stop that.”
“BIO has a position of not standing behind non-competitive pricing schemes that undermine the incentive to innovate,” he added.
Date: November 19, 2018
Source: BioPharma
